All In MedTech

Device Trial Radar · NCT06003608

Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease

Observational, Cross-sectional Clinical Study in Parkinson's Disease (PD) Patients and Healthy Controls (HC) to Identify PD Specific Microbial and Metabolic Fingerprints in Small Intestinal (SI) Fluid and Blood

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

51

Actual

Start

Feb 19, 2024

Primary completion

Jan 1, 2025

Study completion Jan 1, 2025

Sponsor

Lead sponsor
Nimble Science Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
MRM Health NV
First posted
Aug 22, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Observational cross-sectional study in PD patients and healthy controls (HC) using an investigational medical device consisting of a passive small intestine microbiome aspiration (SIMBA) system (capsule) that is ingested orally and recovered together with the stools (home recovery) together with blood sampling (during the onsite visit).

Conditions

  • Parkinson Disease

Interventions

  • Fluid biopsy capsuleDevice

    Ingestion of two SIMBA capsules

  • Levodopa-Carbidopa Immediate ReleaseDrug

    Single dose, Levodopa-Carbidopa Immediate Release

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in microbiome profile of small intestine samples between groupsTime frame: Baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Calgary

    Calgary, Alberta, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.